In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sobel NV

Latest From Sobel NV

Pliva: Two Steps Forward, One Step Back?

After a fervent US expanstion capped by the surprise $150 million licensing of Indevus OAB treatment Sanctura, proprietary ambitions at the Croatian generics play Pliva may be stalling. Sanctura sales have disappointed, illustrating again the challenges of taking a specialist approach to primary care marketing. Pliva's best bet may be to switch growth engines to its promising biogenerics portfolio.
BioPharmaceutical Strategy

Pliva/Indevus: Moving Up the Value Chain

Pliva's not the obvious choice of US marketing partner for Indevus' overactive bladder drug Sanctura. With no primary care presence in the US, the company will likely face an uphill battle to commercialize the drug; more so given the stiff competition in OAB from some of the world's leading Big Pharma marketeers. Yet the deal's about more than success with Sanctura. It's about both parties moving up the value chain--Pliva into the US proprietary drugs arena and Indevus into sales and marketing.
BioPharmaceutical Strategy

Slovenia's Lek Calls Highest Bidder

Novartis' €823 million ($812 million) offer for Slovenia's second largest drug firm looks generous and would give Lek a strong US and EU distribution channel. But Lek's key shareholders think the company can command an even higher price.
BioPharmaceutical Europe

Pliva: Europe is Not Enough

Buying Sobel Holdings makes Croatia's Pliva one of the first eastern European companies to buy into the US market. It's doing so cleverly, leveraging future revenues from its biggest product, azithromycin, to fund the deal, and executing it through a tax-efficient Hungarian subsidiary.
BioPharmaceutical United States
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • Sobel NV
  • Senior Management
  • Daan V Doorh, Pres. & CEO
    Ton Lammers, CFO
  • Contact Info
  • Sobel NV
    Phone: (31) 499 364 555
    NCB Weg 10
    P.O. Box 380 Best, 5681 RH